Scarica l'app Stockscreener
7.67
1.86%
0.14
Precedente Chiudi:
$7.53
Aprire:
$7.56
Volume 24 ore:
2.70M
Relative Volume:
1.86
Capitalizzazione di mercato:
$561.98M
Reddito:
$31,000
Utile/perdita netta:
$-38.18M
Rapporto P/E:
-10.94
EPS:
-0.701
Flusso di cassa netto:
$-38.90M
1 W Prestazione:
+23.71%
1M Prestazione:
+53.40%
6M Prestazione:
+50.69%
1 anno Prestazione:
+54.02%
Intervallo 1D:
$7.49
$7.9884
Intervallo di 1 settimana:
$6.11
$7.9884
Portata 52W:
$4.3384
$7.9884
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.67 | 561.98M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Iniziato | Stephens | Overweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope - Traders Union
Candel to discuss phase 3 prostate cancer trial data on May 15 - Investing.com UK
Candel to discuss phase 3 prostate cancer trial data on May 15 By Investing.com - Investing.com Australia
Candel Therapeutics to review Phase 3 prostate cancer data in May 15 call - Proactive financial news
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - The Manila Times
Candel lines up May 15 call after prostate cancer trial data at AUA - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Candel hires get options to buy 29,400 shares at $6.18 - Stock Titan
Candel Therapeutics (NASDAQ: CADL) details 2026 virtual vote on directors and KPMG - Stock Titan
[ARS] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Small cap wrap: C3 Metals, Candel Therapeutics, BioHarvest Sciences… - Proactive financial news
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch - Yahoo Finance
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - The Manila Times
Candel picks EVERSANA over building its own sales force for prostate launch - Stock Titan
BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
CADL Forecast, Price Target & Analyst Ratings | CANDEL THERAPEUTICS INC (NASDAQ:CADL) - ChartMill
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment.Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Tây Ninh
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - MSN
Mapping Candel Therapeutics' Sprint To The BLA Finish Line - Bioprocess Online
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL) - Seeking Alpha
CADL Initiated Coverage By Cantor Fitzgerald -- Rating Overweigh - GuruFocus
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating - Benzinga
Insiders Rewarded With US$506k Addition To Investment As Candel Therapeutics Stock Hits US$467m - 富途牛牛
Is Candel (CADL) stock forming a continuation pattern (Leaps) 2026-04-20High Interest Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside? - Stocktwits
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Targeted oncology therapies expand industry interest for Candel Therapeutics - Traders Union
Trading Systems Reacting to (CADL) Volatility - Stock Traders Daily
Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a 266.50% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs - Traders Union
Aug Analyst Calls: Should I hold or sell Candel Therapeutics Inc now2026 Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell - MarketBeat
Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026 - Traders Union
Dow Update: Is Candel Therapeutics Inc affected by consumer sentimentMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Winners Losers: Can Candel Therapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn
Should I Buy Candel (CADL) Stock Now | Price at $5.15, Up 3.00%Hedge Fund Favorites - Cổng thông tin điện tử Tỉnh Sơn La
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
CADL Stock Analysis: Candel Therapeutics Inc. Biotech at 5 Dollar Level Post Mild Daily Uptick - Cổng thông tin điện tử tỉnh Tây Ninh
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance UK
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan
Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):